SOMA Research

Retatrutide vs Tirzepatide: Triple and Dual Agonists Compared

Retatrutide and tirzepatide are the two most structurally similar compounds in the SOMA catalogue, and the most frequently compared. Both are 39-amino-acid acylated peptides built on a GIP-analogue backbone. Both engage more than one incretin receptor. The difference between them is one receptor arm — and that single difference is what separates a dual agonist from a triple agonist.

SOMA Research supplies both compounds for laboratory research use only. They are not drugs, supplements, food or cosmetics, are not approved by the FDA for any use, and are not intended for human or veterinary consumption. Nothing below compares them on effectiveness, which this evidence base does not support.

Side by side

Tirzepatide Retatrutide
Catalogue designation GLP-2 TZ GLP-3 RT
Class Dual agonist Triple agonist
Receptors GIP + GLP-1 GIP + GLP-1 + glucagon
CAS number 2023788-19-2 2381089-83-2
Length 39 amino acids 39 amino acids
Molecular weight ~4,813.5 g/mol ~4,731 g/mol
Acylation C20 fatty diacid C20 fatty diacid
Backbone GIP analogue GIP analogue

Full treatments are in the tirzepatide guide and the retatrutide guide.

The glucagon arm is the whole difference

Tirzepatide engages two class B G-protein-coupled receptors: the GIP receptor and the GLP-1 receptor. Both couple primarily to Gs and raise intracellular cAMP. Retatrutide engages those two and adds a third, the glucagon receptor (GCGR).

Why that addition is mechanistically interesting is worth stating precisely. Glucagon signalling has historically been treated as opposed to GLP-1 signalling in glucose regulation — the two arms of a counter-regulatory system. Deliberately building glucagon-receptor activity into an incretin agonist is therefore not an obvious design choice. In the preclinical literature it is studied for effects on hepatic substrate handling and energy expenditure rather than on insulin secretion, which is a different question from the one the dual agonist addresses.

For comparative receptor work this makes the pair genuinely useful. Place a GLP-1 mono-agonist, tirzepatide and retatrutide in one panel and each step adds exactly one signalling arm:

Compound GLP-1 GIP Glucagon
Semaglutide yes — —
Tirzepatide yes yes —
Retatrutide yes yes yes

A difference observed across that series can be attributed to a specific receptor contribution rather than to incretin signalling in general. That is a cleaner design than most compound comparisons allow, and it is the reason the two are usually studied together rather than against each other.

What they share structurally

The similarities are as informative as the difference.

Both are 39 residues on a GIP-analogue backbone. Neither is a modified GLP-1. Starting from GIP and engineering GLP-1 activity into it is the shared design decision underneath both molecules.

Both carry a C20 fatty diacid chain. This is an albumin-binding strategy: the lipid tail binds reversibly to serum albumin, slowing renal clearance and shielding the peptide from enzymatic degradation. Note this is a different use of acylation from tesamorelin, whose short hexenoyl group is a protease shield and far too small for meaningful albumin binding. “Fatty acid modified” on a datasheet covers both strategies and distinguishes neither.

Both use Aib. 2-aminoisobutyric acid is a non-proteinogenic residue that resists dipeptidyl peptidase-4 cleavage and stabilises helical structure. It appears in ipamorelin as well, for the same reason.

An analytical consequence of the similarity

This is the practical part, and it is specific to this pair.

The two molecules differ by roughly 82 daltons on masses near 4,800 — under 2%. They are the same length, built on the same backbone, carrying the same acyl chain, which also means similar hydrophobicity and therefore similar reversed-phase retention.

Compare that to telling KPV (342 g/mol) from BPC-157 (1,420 g/mol): a glance at any mass spectrum settles it. Between retatrutide and tirzepatide, a mislabelling or cross-contamination is a much subtler thing to detect. It is well within the resolving power of competent deconvolution — 82 Da at 4,800 is not a hard measurement — but it requires the instrument and the analyst to be doing the job properly rather than pattern-matching to an expected answer.

Practically, when reading a certificate for either compound: check the observed mass against the theoretical for that specific compound, not just that a mass in the right region was reported. The two figures are close enough that “approximately 4,800” is not a confirmation of identity. Our HPLC vs mass spectrometry guide covers why identity and purity are separate questions, and the CoA guide covers the fields.

Research and regulatory context

Both molecules have been the subject of published clinical investigation by their developer. Those programmes concern pharmaceutical products manufactured to pharmaceutical standards and are cited here only as the published literature on the molecules.

Research-grade material supplied for laboratory use is not those products. It is not manufactured under pharmaceutical quality systems, carries no approval of any kind, and must not be used in or on humans or animals. The existence of a clinical programme for a molecule confers nothing on research-grade material of the same molecule.

Handling

Identical for both, and unremarkable: lyophilised powder at -20°C protected from light; reconstituted stock at 2–8°C, aliquoted, used within approximately 30 days; avoid freeze-thaw cycling. Neither sequence presents the oxidation-prone residues that complicate storage of some shorter peptides. At 39 residues both are long enough that surface adsorption at low working concentrations is worth considering, so low-binding plasticware is sensible for dilute solutions. Procedure and concentration arithmetic are in our reconstitution guide.

Research use only

Research-grade retatrutide and tirzepatide are supplied for laboratory use by qualified researchers and institutions. Neither is manufactured to pharmaceutical standards, neither has been approved by the FDA for any use, and neither must be used in or on humans or animals. Nothing in this guide is medical advice or a representation that either compound is safe or effective for any purpose.